Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.12M Hold
8,686
0.6% 41
2026
Q1
$1.04M Hold
8,686
0.64% 38
2025
Q4
$914K Hold
8,686
0.52% 41
2025
Q3
$729K Hold
8,686
0.4% 48
2025
Q2
$688K Hold
8,686
0.4% 48
2025
Q1
$780K Hold
8,686
0.51% 44
2024
Q4
$864K Hold
8,686
0.52% 42
2024
Q3
$986K Hold
8,686
0.61% 37
2024
Q2
$1.08M Buy
8,686
+42
+0.5% +$5.41K 0.69% 34
2024
Q1
$1.14M Buy
8,644
+2,151
+33% +$265K 0.72% 34
2023
Q4
$725K Hold
6,493
0.61% 31
2023
Q3
$671K Hold
6,493
0.6% 32
2023
Q2
$749K Hold
6,493
0.62% 30
2023
Q1
$718K Buy
6,493
+578
+10% +$62.4K 0.63% 32
2022
Q4
$656K Buy
+5,915
New +$605K 0.6% 32

Other funds holding MRK

General Partner Inc's MRK Position: Q2 2026 in Review

General Partner Inc held its Merck (MRK) position steady in Q2 2026 at 8,686 shares worth $1.12M. The position accounts for 0.6% of the portfolio, ranked #41.

General Partner Inc first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.14M in Q1 2024. 711 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • General Partner Inc held 8,686 shares of Merck worth $1.12M as of Q2 2026.
  • General Partner Inc left its Merck share count unchanged in Q2 2026.
  • Merck made up 0.6% of General Partner Inc's portfolio in Q2 2026, its #41 holding.
  • General Partner Inc first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • General Partner Inc's Merck position peaked at $1.14M in Q1 2024.
  • 711 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on General Partner Inc's 13F filing for Q2 2026, filed 6 Jul 2026.